Humacyte Inc

HUMA | $3.59 15.06% 13.09% 5.7M

(0.0% 1d) (-10.6% 1m) (-6.9% 1y) (0.0% 2d) (2.0% 3d) (8.3% 7d) (-24.76% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 427,510,584
https://humacyte.com
Sec Filling | Patents | n/a employees

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

diabetic diabetes ceiling treatment defense t-cell

add to watch list Paper trade email alert is off

Press-releases

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
Published: 2024-03-26 (Crawled : 20:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| 1.63% | O: 2.61% H: 2.86% C: -1.59%

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
Published: 2024-03-22 (Crawled : 11:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| -13.33% | O: 0.83% H: 0.83% C: -8.82%
business year update financial results

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| -3.7% | O: 5.86% H: 5.25% C: 2.33%
update financial results

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
Published: 2024-03-01 (Crawled : 14:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| -28.28% | O: -31.03% H: 17.0% C: 8.0%
conference health care

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
Published: 2024-03-01 (Crawled : 03:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| -28.28% | O: -31.03% H: 17.0% C: 8.0%
million offering

Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| -28.28% | O: -31.03% H: 17.0% C: 8.0%
offering

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
Published: 2024-02-09 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| -0.48% | O: 8.13% H: 7.96% C: 7.08%
fda license granted review treatment application

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
Published: 2023-12-12 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| 13.87% | O: 0.36% H: 2.18% C: -0.36%
fda license approval treatment application

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
Published: 2023-11-24 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.7M

Manufacturing

| 22.35% | O: 0.39% H: 5.66% C: 1.17%
conference